Introduction As a common autoimmune disease with the characteristic of early complication,
primary biliary cholangitis (PBC) leads to an increasing number of mortalities among people …

Abstract Introduction and Objectives Primary biliary cholangitis (PBC) is an autoimmune liver
disease, with 60% of patients being asymptomatic at diagnosis and 30% progressing rapidly …

Biliary tract infection (BTI), a commonly occurring abdominal disease, despite being
extensively studied for its initiation and underlying mechanisms, continues to pose a …

Aim: Up to 40% of patients with primary biliary cholangitis (PBC) will have a suboptimal
biochemical response to ursodeoxycholic acid (UDCA), which can be improved by the …

Objective Primary biliary cholangitis is a chronic and progressive autoimmune liver disease,
whose prognosis can be improved by normalizing alkaline phosphatase and bilirubin. While …

Background Response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC)
has been traditionally assessed 1 to 2 years after treatment initiation. With the development …

Introduction and objectives Primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH)
and PBC overlap syndrome (AIH/PBC) have been associated with a higher risk of …

Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic disease characterized
by the destruction of the small intrahepatic bile ducts, which can progress to liver cirrhosis …

Introduction In primary biliary cholangitis (PBC), approximately 40% of the patients respond
incompletely to first-line treatment with ursodeoxycholic acid (UDCA), resulting in a poorer …

Background Ursodeoxycholic acid (UDCA) is the standard treatment for primary biliary
cholangitis (PBC), but a significant proportion of patients do not respond adequately, leading …